The data obtained from CD4‐depleting mAb trials in MS may therefore provide only a weak argument against T cells being important in MS and indeed long‐term and marked (95–70%) depletion of CD4‐ and CD8‐positive T cells with alemtuzumab are associated with inhibition of the development of relapses in MS.12 Here, CD8A is linked to myeloid sarcoma.